Daily Archives: November 8, 2007

El sobrepreso disminuye la mortalidad: l@s gordit@s festejan


Hace alrededor de dos años, un equipo de científicos estatales informó que las personas con sobrepeso tienen una tasa de mortalidad más baja que las personas con peso normal, bajo peso u obesas. Ahora, después de seguir investigando, el mismo … Continue reading

Posted in mortalidad, Sobrepeso | Tagged , , , , | Leave a comment

Solicitud de Moratoria para la aplicacion de la vacuna para HPV en España


Invitamos a todos los amigos que nos leen desde España a la firma de este documento el cual se encuentra en http://www.caps.pangea.org/declaracion/ Recientemente el Consejo Interterritorial del Sistema Nacional de Salud (SNS) ha dado luz verde a la inclusión en … Continue reading

Posted in Inmmunizacion, Virus Papiloma Humano | Tagged , , , , , | 2 Comments

Estudio SMART: salmeterol y asma A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More… Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com Abstract Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study. Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks. Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded. Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI. Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo. Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown. Estudio SMART: The Salmeterol Multicenter Asthma Research Trial


The Salmeterol Multicenter Asthma Research Trial A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the … Continue reading

Posted in Asma, Medicamentos, mortalidad, Salud Infantil | Tagged , , , , | Leave a comment

Estudio SMART: salmeterol y asma A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More… Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com Abstract Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study. Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks. Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded. Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI. Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo. Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown. Estudio SMART: The Salmeterol Multicenter Asthma Research Trial


The Salmeterol Multicenter Asthma Research Trial A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the … Continue reading

Posted in Asma, Medicamentos, mortalidad, Salud Infantil | Tagged , , , , , | Leave a comment

Pediatria


1st edition By Janner, Donald Download Clinical Guide to Pediatric Infectious Disease PASSWORD FOR OPEN RAR FILE IS http://medicalbooks4everyone.blogspot.com/

Posted in Biblioteca virtual, Infectologia, Salud Infantil | Tagged , , , , | Leave a comment

Comparative accuracy: assessing new tests against existing diagnostic pathways


Development and introduction of new diagnostic techniques have greatly accelerated over the past decades. The evaluation of diagnostic techniques, however, is less advanced than that of treatments. Unlike with drugs, there are generally no formal requirements for adoption of diagnostic … Continue reading

Posted in Diagnostico | Tagged , , , | Leave a comment

Estudio SMART: opinion del Instituto Catalan de Farmacologia


El analisis de dicho estudio por el ICF puede ser visto en http://www.icf.uab.es/WebsietesDB/shortcut.asp?refid=75959

Posted in Asma, Medicamentos | Tagged , , , , | 1 Comment

* Deteccion de enfermedades congenitas * Proyecto de normativa para celiacos en el Partido de Pehuajó (prov. Bs. As.) * We stand all toguether * Vacuna antineumococcica Salud en niños


Deteccion de enfermedades congenitas Proyecto de normativa para celiacos en el Partido de Pehuajó (prov. Bs. As.) We stand all toguether Vacuna antineumococcica Fuente: http://pedamb.wordpress.com

Posted in Salud Infantil | Tagged , , , , , , , | Leave a comment

* Deteccion de enfermedades congenitas * Proyecto de normativa para celiacos en el Partido de Pehuajó (prov. Bs. As.) * We stand all toguether * Vacuna antineumococcica Salud en niños


Deteccion de enfermedades congenitas Proyecto de normativa para celiacos en el Partido de Pehuajó (prov. Bs. As.) We stand all toguether Vacuna antineumococcica Fuente: http://pedamb.wordpress.com

Posted in Salud Infantil | Tagged , , , , , , , , | Leave a comment

Internaciones psiquiatricas


El 85 por ciento de los pacientes con afecciones psiquiátricas que se encuentran en centros de salud públicos y privados son internados por orden judicial en Argentina, mientras especialistas reclamaron la participación de equipos de salud mental para determinar si … Continue reading

Posted in Salud mental | Tagged , , , , , , | Leave a comment